Mary K. McKenna
YOU?
Author Swipe
View article: Data from Tunneling CARs: Increasing CAR T-Cell Tumor Infiltration through the Overexpression of MMP-7 and Osteopontin-b
Data from Tunneling CARs: Increasing CAR T-Cell Tumor Infiltration through the Overexpression of MMP-7 and Osteopontin-b Open
Chimeric antigen receptor (CAR) T-cell therapy has demonstrated remarkable efficacy against hematologic malignancies but has struggled to achieve comparable success in solid tumors. A key obstacle in solid tumors is the extracellular matri…
View article: Supplementary Figure 1 from Tunneling CARs: Increasing CAR T-Cell Tumor Infiltration through the Overexpression of MMP-7 and Osteopontin-b
Supplementary Figure 1 from Tunneling CARs: Increasing CAR T-Cell Tumor Infiltration through the Overexpression of MMP-7 and Osteopontin-b Open
OPN or MMP-7 expression enhances primary T cell movement through ECM.
View article: Supplementary Table 1 from Tunneling CARs: Increasing CAR T-Cell Tumor Infiltration through the Overexpression of MMP-7 and Osteopontin-b
Supplementary Table 1 from Tunneling CARs: Increasing CAR T-Cell Tumor Infiltration through the Overexpression of MMP-7 and Osteopontin-b Open
Summary of gene sets used for candidate gene identification.
View article: Supplementary Figure 3 from Tunneling CARs: Increasing CAR T-Cell Tumor Infiltration through the Overexpression of MMP-7 and Osteopontin-b
Supplementary Figure 3 from Tunneling CARs: Increasing CAR T-Cell Tumor Infiltration through the Overexpression of MMP-7 and Osteopontin-b Open
Activation and exhaustion signatures are not dependent on MMP-7 or OPN expression.
View article: Supplementary Figure 4 from Tunneling CARs: Increasing CAR T-Cell Tumor Infiltration through the Overexpression of MMP-7 and Osteopontin-b
Supplementary Figure 4 from Tunneling CARs: Increasing CAR T-Cell Tumor Infiltration through the Overexpression of MMP-7 and Osteopontin-b Open
CAR T cell-derived OPN does not affect macrophage phenotype in vitro.
View article: Supplementary Figure 5 from Tunneling CARs: Increasing CAR T-Cell Tumor Infiltration through the Overexpression of MMP-7 and Osteopontin-b
Supplementary Figure 5 from Tunneling CARs: Increasing CAR T-Cell Tumor Infiltration through the Overexpression of MMP-7 and Osteopontin-b Open
CAR T cell-derived OPN does not enhance suppressive effects of MSCs on T cell proliferation in vitro.
View article: Supplementary Figure 2 from Tunneling CARs: Increasing CAR T-Cell Tumor Infiltration through the Overexpression of MMP-7 and Osteopontin-b
Supplementary Figure 2 from Tunneling CARs: Increasing CAR T-Cell Tumor Infiltration through the Overexpression of MMP-7 and Osteopontin-b Open
MMP-7 and OPN expression in GD2.CAR T cells increases their infiltration in vitro.
View article: Supplementary Figure 6 from Tunneling CARs: Increasing CAR T-Cell Tumor Infiltration through the Overexpression of MMP-7 and Osteopontin-b
Supplementary Figure 6 from Tunneling CARs: Increasing CAR T-Cell Tumor Infiltration through the Overexpression of MMP-7 and Osteopontin-b Open
OPN expression in GD2.CAR T cells enhances tumor clearance in xenograft model of NB without increasing non-specific infiltration.
View article: Supplementary Table 1 from Endoglin-Directed CAR T Cells Comprehensively Target Tumors in Advanced Sarcomas
Supplementary Table 1 from Endoglin-Directed CAR T Cells Comprehensively Target Tumors in Advanced Sarcomas Open
List of antibodies and reagents used in the study.
View article: Supplementary Figure 2 from Endoglin-Directed CAR T Cells Comprehensively Target Tumors in Advanced Sarcomas
Supplementary Figure 2 from Endoglin-Directed CAR T Cells Comprehensively Target Tumors in Advanced Sarcomas Open
ENG CAR design and molecular modeling.
View article: Supplementary Figure 3 from Endoglin-Directed CAR T Cells Comprehensively Target Tumors in Advanced Sarcomas
Supplementary Figure 3 from Endoglin-Directed CAR T Cells Comprehensively Target Tumors in Advanced Sarcomas Open
Activation induced cytokine release and proliferation of ENG CAR-T.
View article: Supplementary Figure 5 from Endoglin-Directed CAR T Cells Comprehensively Target Tumors in Advanced Sarcomas
Supplementary Figure 5 from Endoglin-Directed CAR T Cells Comprehensively Target Tumors in Advanced Sarcomas Open
Efficacy of ENG CAR-T in orthotopic xenograft models of sarcoma.
View article: Supplementary Figure 6 from Endoglin-Directed CAR T Cells Comprehensively Target Tumors in Advanced Sarcomas
Supplementary Figure 6 from Endoglin-Directed CAR T Cells Comprehensively Target Tumors in Advanced Sarcomas Open
The c-SN6j/TRC105 antibody does not recognize murine or rhesus endoglin.
View article: Supplementary Figure 4 from Endoglin-Directed CAR T Cells Comprehensively Target Tumors in Advanced Sarcomas
Supplementary Figure 4 from Endoglin-Directed CAR T Cells Comprehensively Target Tumors in Advanced Sarcomas Open
Binding of recombinant ENG to CAR-T.
View article: Data from Endoglin-Directed CAR T Cells Comprehensively Target Tumors in Advanced Sarcomas
Data from Endoglin-Directed CAR T Cells Comprehensively Target Tumors in Advanced Sarcomas Open
There are limited therapeutic options for patients with advanced sarcomas, which leads to dismal outcomes for children and adults. Although chimeric antigen receptor (CAR) T cells hold promise for treating advanced sarcomas, this approach …
View article: Supplementary Table 2 from Endoglin-Directed CAR T Cells Comprehensively Target Tumors in Advanced Sarcomas
Supplementary Table 2 from Endoglin-Directed CAR T Cells Comprehensively Target Tumors in Advanced Sarcomas Open
Rhabdomyosarcoma cell lines with transcript expression of ENG, CD44, CD70, and CD90 from the CCLE public release 24Q4 with fusion status and histology.
View article: Supplementary Figure 1 from Endoglin-Directed CAR T Cells Comprehensively Target Tumors in Advanced Sarcomas
Supplementary Figure 1 from Endoglin-Directed CAR T Cells Comprehensively Target Tumors in Advanced Sarcomas Open
ENG expression in sarcoma tissues and cell lines.
View article: Peritoneal Immunosurgery: Immunotherapy Augmented Surgery for the Treatment of Peritoneal Cancers
Peritoneal Immunosurgery: Immunotherapy Augmented Surgery for the Treatment of Peritoneal Cancers Open
Peritoneal malignancy often indicates disruptions in multiple physiological systems resulting from widespread cancer. The heterogenous origin and dynamic nature of peritoneal cancer make it difficult to treat with standard approaches that …
View article: IL-7 armed binary CAR T cell strategy to augment potency against solid tumors
IL-7 armed binary CAR T cell strategy to augment potency against solid tumors Open
Introduction Clinical studies of T cells engineered with chimeric antigen receptor (CAR) targeting CD19 in B-cell malignancies have demonstrated that relapse due to target antigen (CD19) loss or limited CAR T cell persistence is a common o…
View article: IL-7 armed binary CAR T cell strategy to augment potency against solid tumors
IL-7 armed binary CAR T cell strategy to augment potency against solid tumors Open
Clinical studies of T cells engineered with chimeric antigen receptor (CAR) targeting CD19 in B-cell malignancies have demonstrated that relapse due to target antigen (CD19) loss or limited CAR T cell persistence is a common occurrence. Th…
View article: 294 Banana lectin CAR T cells to target pancreatic cancer
294 Banana lectin CAR T cells to target pancreatic cancer Open
View article: Mesenchymal stromal cells protect combined oncolytic and helper-dependent adenoviruses from humoral immunity
Mesenchymal stromal cells protect combined oncolytic and helper-dependent adenoviruses from humoral immunity Open
Systemic delivery of oncolytic and immunomodulatory adenoviruses may be required for optimal effects on human malignancies. Mesenchymal stromal cells (MSCs) can serve as delivery systems for cancer therapeutics due to their ability to tran…
View article: A dual-luciferase bioluminescence system for the assessment of cellular therapies
A dual-luciferase bioluminescence system for the assessment of cellular therapies Open
View article: Novel banana lectin CAR-T cells to target pancreatic tumors and tumor-associated stroma
Novel banana lectin CAR-T cells to target pancreatic tumors and tumor-associated stroma Open
Background Cell therapies for solid tumors are thwarted by the hostile tumor microenvironment (TME) and by heterogeneous expression of tumor target antigens. We address both limitations with a novel class of chimeric antigen receptors base…
View article: Targeting glycans for CAR therapy: The advent of sweet CARs
Targeting glycans for CAR therapy: The advent of sweet CARs Open
View article: Impact of Manufacturing Procedures on CAR T Cell Functionality
Impact of Manufacturing Procedures on CAR T Cell Functionality Open
The field of chimeric antigen receptor (CAR) modified T cell therapy has rapidly expanded in the past few decades. As of today, there are six CAR T cell products that have been approved by the FDA: KYMRIAH (tisagenlecleucel, CD19 CAR T cel…
View article: Generation of CAR T-cells using γ-retroviral vector
Generation of CAR T-cells using γ-retroviral vector Open
View article: Combinatorial antigen targeting strategies for acute leukemia: application in myeloid malignancy
Combinatorial antigen targeting strategies for acute leukemia: application in myeloid malignancy Open
View article: Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer
Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer Open
Background Successful targeting of solid tumors such as breast cancer (BC) using chimeric antigen receptor (CAR) T cells has proven challenging, largely attributed to the immunosuppressive tumor microenvironment (TME). Myeloid-derived supp…
View article: Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity
Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity Open